Blog

  • Investors use dotcom era playbook to dodge AI bubble risks

    Investors use dotcom era playbook to dodge AI bubble risks

    Major investors, spooked by AI exuberance yet wary of betting against it, are shifting from hyped-up stocks into potential next-in-line winners, reviving a strategy from the 1990s dotcom era that helped some sidestep the crash.

    As U.S. stocks have hit successive records and AI chipmaker Nvidia’s valuation has surged beyond $4 trillion, professional investors have been trying to find ways to make money from the bull market while avoiding excessive risk.

    Some are looking back to the 1990s internet boom, which spread from startups to telecoms and tech, and where hedge funds rode the wave by flipping out of highly-valued stocks before they peaked and picking others that had room to rise.

    “What we are doing is what worked from 1998 to 2000,” said Francesco Sandrini, multi-asset head and Italy CIO at Europe’s largest asset manager Amundi.

    He highlighted signs of irrational exuberance on Wall Street, such as frenzied trading in risky options pegged to the share prices of big AI stocks. But he said he expected the new tech enthusiasm to continue and hoped to bank gains via bets on reasonably valued assets that might rally next.

    Sandrini said this involved trying to find “the highest growth opportunities that so far the market had failed to spot”, with moves into software groups, robotics and Asian tech.

    Other investors also expected to edge out of Wall Street’s Magnificent Seven stocks after shares in Nvidia more than tripled in two years, but want to keep their diversification within the AI sphere.

    ASSET MANAGERS NEED TO BE NIMBLE TO RIDE THE WAVE

    “The odds of this (AI boom) being a bust are very high because you’ve got companies spending trillions and all fighting for the same market that does not yet exist,” said Goshawk Asset Management CIO Simon Edelsten, who worked on telecom IPOs at stockbroker Dresdner Kleinwort Benson in London in 1999.

    He expected the next phase of AI fever to spread from Nvidia and others like Microsoft and Alphabet into
    related sectors.

    Timing the phases of a bubble has historically been a way to play it without the risk of trying to call the peak too early.

    A study by economists Markus Brunnermeir and Stefan Nagel showed that hedge funds mostly did not bet against the dotcom bubble, but rode it skillfully enough to beat the market by about 4.5% per quarter from 1998-2000 and avoid the worst of the downturn.

    They shed high-priced internet stocks in time to recycle profits into others before they caught the attention of less sophisticated investors.

    “There were good profits to be made for the fleet of foot even during 2000 when the top came,” Edelsten at Goshawk said, adding the current market environment was similar to 1999.

    He favoured IT consultants and Japanese robotics groups that can potentially pick up revenues from AI heavyweights, in what he said was the typical chronology of a market gold rush.

    “When someone strikes gold, (you) buy the local hardware store where the prospectors will buy all their shovels.”

    INVESTORS TRY TO STAY IN AI WITHOUT EXCESSIVE RISK

    Investors are also attempting to benefit from the trillion of dollars so-called hyperscalers such as Amazon, Microsoft and Alphabet are committing to AI data centres and advanced chips without taking on more direct exposure to these companies.

    Fidelity International multi-asset manager Becky Qin said uranium was her favoured new AI trade because power-hungry AI data centres could gobble up nuclear energy.

    Kevin Thozet, investment committee member at asset manager Carmignac, was taking profits on Magnificent Seven stocks and building up a position in Taiwan’s Gudeng Precision, which makes delivery boxes for AI chipmakers including TSMC.

    Asset managers are also concerned that the rush to build data centres could result in overcapacity, as in the fiber-optic cable boom in the telecoms industry.

    “In any new technological paradigm we don’t get from A to B without excesses along the way,” said Pictet Asset Management senior multi-asset strategist Arun Sai.

    Even though top AI stocks like Microsoft, Amazon, and Alphabet are being powered by strong earnings, he still sees “the building blocks of a bubble” and favours Chinese stocks as a hedge if rapid AI advancements in China sap Wall Street’s AI enthusiasm.

    Some investors, though, do not favour this relative value approach to AI investing as a way to mitigate future losses.

    Oliver Blackbourn, portfolio manager at Janus Henderson, said he was hedging his U.S. tech positions with European and healthcare assets lest an AI stock crash takes the U.S. economy down with it.

    He said it was impossible to forecast how long the AI craze would roll on because calling the peak was usually only possible with hindsight.

    “We’re in 1999 until the bubble pops.”

    Published – October 25, 2025 09:55 am IST

    Continue Reading

  • Lahore tops global pollution index with hazardous air quality

    Lahore tops global pollution index with hazardous air quality



    Student rides a bicycle to school amid dense smog in Lahore, November 24, 2021. —…

    Continue Reading

  • Real-World Outcomes From Third-Line SCLC Treatment Show Need for More Options

    Real-World Outcomes From Third-Line SCLC Treatment Show Need for More Options

    Patients with extensive-stage small cell lung cancer (ES-SCLC) see little benefit from third-line (3L) therapies, according to a new analysis of real-world outcomes.1 The authors of the analysis say it underscores the “urgent” need for novel…

    Continue Reading

  • Dassault Systèmes (ENXTPA:DSY) Margin Decline Challenges Bullish Narratives Despite Strong Recurring Revenue

    Dassault Systèmes (ENXTPA:DSY) Margin Decline Challenges Bullish Narratives Despite Strong Recurring Revenue

    Dassault Systèmes (ENXTPA:DSY) reported annual earnings growth of 1.2%, a significant slowdown from its five-year average of 16.7%. Net profit margins slipped to 18% from last year’s 18.5%, while earnings are forecast to grow 10.2% per year, trailing the broader French market’s 12.2% outlook. The company’s revenue is expected to rise by 6.2% per year, outpacing the French market average of 5.4%. With the share price closing at €25.69, the results point to a period of slower but still positive growth. Profitability remains healthy and the stock trades slightly below its estimated fair value, leaving room for optimism among value-focused investors.

    See our full analysis for Dassault Systèmes.

    With the headline results in place, the next step is to see how these figures compare to the prevailing narratives that investors follow. We will set the latest numbers alongside the stories shaping market sentiment to spot where the consensus holds up or gets tested.

    See what the community is saying about Dassault Systèmes

    ENXTPA:DSY Earnings & Revenue History as at Oct 2025
    • 83% of Dassault Systèmes’ software revenues are now recurring, reflecting the steady expansion of its subscription business and supporting analysts’ expectations that profit margins will rise from 18.0% today to 22.3% over the next three years.

    • According to the analysts’ consensus view, predictable subscription streams and strong adoption of cloud-based and AI-powered products should structurally elevate net margins, especially as momentum builds across diverse industries and geographies.

      • The transition to subscription models anchors future profitability as recurring revenue streams offset near-term fluctuations in deal volume.

      • However, the consensus also notes that new product launches in high-growth sectors must overcome delays and execution challenges to fully realize this margin upside.

    • If you want to see how analysts think the cloud and recurring revenue story could supercharge margins, don’t miss the full details in the consensus narrative. 📊 Read the full Dassault Systèmes Consensus Narrative.

    • Analysts forecast Dassault Systèmes’ revenue will rise 6.2% annually over the next three years, exceeding the French market’s expected 5.4% growth, while earnings could reach €1.7 billion by 2028.

    • The analysts’ consensus view heavily supports the bullish case that expanding into high-growth verticals and accelerating adoption of cloud, AI, and automation offerings will drive double-digit earnings growth for years ahead.

      • Strong 3DEXPERIENCE and AI-powered product uptake is broadening the addressable market and positioning the company for subscription-led, higher-margin growth.

      • Continued investment in R&D and targeted acquisitions are intended to enhance competitive advantage, but analysts caution that execution risks in new sectors, especially Life Sciences, could moderate the growth trajectory.

    Continue Reading

  • Should Zimmer Biomet’s AI-Powered Orthopedic Robotics Launch Prompt Action From ZBH Investors?

    Should Zimmer Biomet’s AI-Powered Orthopedic Robotics Launch Prompt Action From ZBH Investors?

    • Earlier this week, Zimmer Biomet Holdings showcased its latest orthopedic robotics and digital health innovations, including FDA-cleared mBos TKA System and the recently acquired Monogram Technologies robotic platform, at the annual meeting of the American Association of Hip and Knee Surgeons.

    • A standout revelation was the integration of AI-driven and autonomous technologies into the company’s expanding knee and hip portfolios, reflecting Zimmer Biomet’s commitment to advancing surgical precision and connected care solutions.

    • We’ll examine how Zimmer Biomet’s integration of AI-driven orthopedic robotics could reshape the long-term outlook for its investment narrative.

    Trump has pledged to “unleash” American oil and gas and these 22 US stocks have developments that are poised to benefit.

    To be a shareholder in Zimmer Biomet, you need to believe in the power of innovation in orthopedic robotics and digital health to drive demand for advanced surgical solutions. This week’s showcase of FDA-cleared and AI-powered products could energize sentiment but is unlikely to meaningfully shift the company’s near-term reliance on successful product launches; ongoing industry pricing pressures still remain the key headwind.

    Among the latest announcements, the FDA clearance of the mBos TKA System stands out for its relevance, as it highlights Zimmer Biomet’s efforts to keep pace in the competitive race for autonomous robotics and supports the company’s narrative of product-driven growth, even as full regulatory approvals for other key technologies remain pending.

    In contrast, investors should be aware of increasing pricing pressures and the consequences if these persist through…

    Read the full narrative on Zimmer Biomet Holdings (it’s free!)

    Zimmer Biomet Holdings is projected to reach $9.2 billion in revenue and $1.3 billion in earnings by 2028. This outlook assumes a 5.5% annual revenue growth rate and an earnings increase of about $476 million from the current $823.5 million.

    Uncover how Zimmer Biomet Holdings’ forecasts yield a $110.92 fair value, a 8% upside to its current price.

    ZBH Community Fair Values as at Oct 2025

    Simply Wall St Community members estimate fair value for Zimmer Biomet anywhere between US$95 and US$167.48 per share, with three unique perspectives. As these opinions range widely, consider the risk of ongoing pricing pressures that could challenge margin recovery and ultimately affect future earnings.

    Explore 3 other fair value estimates on Zimmer Biomet Holdings – why the stock might be worth 8% less than the current price!

    Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.

    The market won’t wait. These fast-moving stocks are hot now. Grab the list before they run:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include ZBH.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Vaisala (HLSE:VAIAS) Earnings Beat 5-Year Trend, Margin Gains Reinforce Bullish Narratives

    Vaisala (HLSE:VAIAS) Earnings Beat 5-Year Trend, Margin Gains Reinforce Bullish Narratives

    Vaisala Oyj (HLSE:VAIAS) delivered another robust earnings performance, with profits expanding at 16.7% over the past year and a five-year compound annual growth rate of 12.8%. The company’s net profit margin rose to 10.9% from last year’s 10.1%, underscoring improved efficiency. Revenue growth of 6.1% per year continues to outpace the broader Finnish market. With forward earnings growth projected at 13.8% per year and no notable risks flagged, investors are likely to focus on the momentum in margins and the sustainability of this positive trend.

    See our full analysis for Vaisala Oyj.

    Next up, we’ll put the latest numbers head-to-head with the current narratives, breaking down where sentiment aligns with the data and where surprises might emerge.

    See what the community is saying about Vaisala Oyj

    HLSE:VAIAS Earnings & Revenue History as at Oct 2025
    • Vaisala’s current share price of €44.95 trades below its DCF fair value estimate of €49.76, signaling about an 11% discount to modeled intrinsic worth.

    • According to analysts’ consensus view, broader value discussions also reference a Price-To-Earnings ratio of 25.7x. This is just below the European Electronic industry average of 26x and above the peer group’s 21.4x.

      • This sector-relative valuation is seen as reasonable, especially since earnings have expanded by 12.8% per year over the past five years. Consensus believes this trend supports the view that Vaisala’s quality and growth justifies its mild premium to local peers.

      • At the same time, consensus highlights potential upside, noting the current share price remains 17.3% below the latest analyst price target of €53.60.

    See what else analysts are tracking in Vaisala’s growth and value story: 📊 Read the full Vaisala Oyj Consensus Narrative.

    • Rapid growth in digital services, such as subscription-based offerings, has driven segment-level sales expansion. Recurring software revenues (e.g., Xweather) saw 53% year-on-year growth, raising hopes for additional gross margin upside as these higher-margin business lines scale.

    • Consensus narrative spotlights diversification into digital and industrial segments as a catalyst for dependable, broad-based margin growth.

      • With analysts forecasting profit margins to rise from 10.9% to 12.3% over three years, the consensus story emphasizes these gains could make earnings quality more resilient, especially as digitalization and R&D outlays underpin proprietary advantages for Vaisala.

      • This long-term thesis leans on proven agility in managing price increases and coping with tariff impacts, providing some protection in an unpredictable environment.

    Continue Reading

  • Mounira Al Solh: Nassib’s Bakery—Distributing Warmth – Announcements

    Mounira Al Solh: Nassib’s Bakery—Distributing Warmth – Announcements

    Kunsthuis SYB is excited to introduce Nassib’s Bakery: Distributing Warmth, a project initiated by Mounira Al Solh, transforming SYB’s front room into a saj bakery this fall.

    Nassib’s Bakery: Distributing Warmth is a re-enactment and…

    Continue Reading

  • Exploring Valuation as Leadership Prepares for Ignite Investment Summit Presentation

    Exploring Valuation as Leadership Prepares for Ignite Investment Summit Presentation

    Paradigm Biopharmaceuticals (ASX:PAR) is drawing investor attention this week as its founder and executive chairman, Paul John Rennie, is set to present at the Ignite Investment Summit in Hong Kong. Events like these often prompt curiosity about possible updates or strategic direction from company leadership.

    See our latest analysis for Paradigm Biopharmaceuticals.

    Paradigm Biopharmaceuticals has seen momentum build sharply in recent weeks, with a 1-month share price return of 55% and a 1-year total shareholder return exceeding 100%. This surge comes as anticipation grows around the company’s presentation at the Ignite Investment Summit. This suggests renewed optimism about its growth prospects and potential strategic updates from leadership.

    If you’re keeping an eye on the biotech space and want to spot more opportunities, it’s a good time to explore See the full list for free.

    With shares soaring and the valuation gap to analyst targets still wide, the central question is whether Paradigm Biopharmaceuticals is still trading below its fair value or if this rally has fully priced in its future growth potential.

    Paradigm Biopharmaceuticals’ widely followed valuation narrative puts its estimated fair value at A$5.50, a dramatic difference from the latest close at A$0.44. The stage is set for a crucial inflection point as investors closely watch the path to commercialization and regulatory approval.

    Paradigm Biopharmaceuticals (ASX: PAR), a late-stage drug development company, is poised at a critical juncture as it progresses its lead drug candidate, Zilosul® (injectable pentosan polysulfate sodium), through Phase 3 clinical trials for the treatment of osteoarthritis (OA). A successful outcome and subsequent clearance from the U.S. Food and Drug Administration (FDA) could unlock a multi-billion dollar market and fundamentally reshape the company’s future, offering a new treatment paradigm for millions suffering from the debilitating joint disease.

    Read the complete narrative.

    This valuation is built on bold assumptions. The projection banks on a pivotal FDA approval, ambitious rollout plans, and pricing power that could shake up the osteoarthritis treatment market. Do you want to know which financial forecasts drive the massive fair value gap? Discover what underpins this blockbuster thesis in the complete narrative.

    Result: Fair Value of $5.50 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, setbacks in pivotal clinical trials or regulatory hurdles could quickly undermine the current optimism surrounding Paradigm Biopharmaceuticals’ valuation outlook.

    Find out about the key risks to this Paradigm Biopharmaceuticals narrative.

    If you see the story differently or prefer independent analysis, you can quickly build your own perspective with our easy-to-use narrative tool in just a few minutes, so Do it your way.

    A great starting point for your Paradigm Biopharmaceuticals research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.

    Don’t let exceptional opportunities slip by while you focus on just one company. Maximize your potential returns by exploring the new directions the market is offering right now.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include PAR.AX.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Ferrari SC40 revives the spirit of the F40 with a modern, hybrid twist

    Ferrari SC40 revives the spirit of the F40 with a modern, hybrid twist

    • The Ferrari SC40 is a one-off berlinetta based on the 296 GTB, producing 610kW and 740Nm of torque.
    • Its design pays tribute to the 1987 F40, featuring angular geometry and a fixed rear wing.
    • Carbon-Kevlar elements and hybrid V6 tech link the…

    Continue Reading

  • Evaluating Valuation Following Recent Share Price Fluctuations

    Evaluating Valuation Following Recent Share Price Fluctuations

    Thales (ENXTPA:HO) shares recently saw some movement, drawing attention to how investors are weighing the company’s momentum over the past year. Its recent returns spark interesting discussions about long-term strategy and sector positioning.

    See our latest analysis for Thales.

    Thales’s recent share price action, including a modest dip to €253.4 after a sharp year-to-date surge, reflects the market’s recognition of its strong operational momentum. The 1-year total shareholder return of 69.57% and a huge 5-year return over 400% suggest that momentum remains firmly in Thales’s favor, which hints at investor optimism about its long-term prospects even with some near-term fluctuations.

    If you’re curious what other companies are drawing attention in this space, check out the full list of aerospace and defense stocks in the following section: See the full list for free.

    With a nearly 70% return in just one year but shares now hovering close to analyst targets, the key question now is whether Thales is undervalued or if the market already anticipates its future growth. Could this be a true buying opportunity?

    The most widely followed narrative puts Thales’s fair value meaningfully above its last close at €253.4. This scenario creates a compelling opportunity for investors weighing current optimism against future growth expectations.

    Heightened innovation and R&D in next-generation technologies (AI, secure communications, space tech, digitization), along with cross-business synergies from acquisitions, position Thales to remain a market leader amid secular shifts toward digital transformation in security, favorably impacting long-term revenue growth and margin resilience.

    Read the complete narrative.

    Want to know the drivers behind this bullish outlook? The most intriguing part is how bold revenue and margin forecasts converge with shifting industry trends. The real surprise lies in the financial leap analysts are betting on. What key growth rate and profit assumptions are they making? Dive in to see what’s fueling this ambitious fair value calculation.

    Result: Fair Value of €275.56 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, execution challenges in Thales’s digital transformation or unexpected government budget delays could quickly temper the current bullish outlook.

    Find out about the key risks to this Thales narrative.

    The market seems excited by Thales’s growth story, but a look at its price-to-earnings ratio gives pause. Thales trades at 49.8x earnings, which is far higher than its peers (31.9x) and even higher than the industry standard (35.2x). This premium suggests buyers are taking on extra valuation risk if optimism fades.

    See what the numbers say about this price — find out in our valuation breakdown.

    ENXTPA:HO PE Ratio as at Oct 2025

    If you see things differently or want to put the numbers to the test yourself, you can easily craft your own Thales narrative in just a few minutes. Do it your way

    A great starting point for your Thales research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

    Opportunities extend far beyond this single stock, and the right screener can help you spot hidden gems, growing sectors, and income powerhouses before others catch on. Make sure you’re keeping an edge by checking out these handpicked options:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include HO.PA.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading